Erika Matos

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

Fátima Cardoso, Laura J. van’t Veer, Jan Bogaerts et al. · New England Journal of Medicine · 2016 · 2.1K citations · Full text

Medicine, Genetics, Oncology +16

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

Jesse J. Swen, Cathelijne H. van der Wouden, Lisanne E. N. Manson et al. · The Lancet · 2023 · 514 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age

Martine Piccart, Laura van ‘t Veer, Coralie Poncet et al. · The Lancet Oncology · 2021 · 358 citations · Full text

Life Sciences, Biostatistics, Oncology +13

Triple negative breast cancer - prognostic factors and survival

Tanja Ovčariček, S. Grazio Frkovic, Erika Matos et al. · Radiology and Oncology · 2011 · 230 citations · Full text

Medicine, Oncology, Breast Oncology +16

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Thomas Bachelot, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2019 · 113 citations · Full text

Medicine, Oncology, Pharmacology +17